Showing 6341-6350 of 6784 results for "".
- Nextech Systems and Iagnosis Showcase New Partnershiphttps://practicaldermatology.com/news/nextech-systems-and-iagnosis-showcase-new-partnership/2458982/Nextech, a leading provider of specialty-focused healthcare technology solutions for physician practices, announced an exclusive partnership with Iagnosis, a leading telemedicine provider of online dermatology solutions. Iagnosis provides a teledermatolog
- Dermira Presents Clinical Data for DRM01 Acne Programhttps://practicaldermatology.com/news/dermira-presents-clinical-data-for-drm01-acne-program/2458981/Dermira, Inc. presented clinical data from its DRM01 Phase 2a trial in patients with facial acne vulgaris. The primary endpoints in this trial, the changes from baseline in inflammatory and non-inflammatory lesion counts and an improvement in the Investigator's Global Assessment (IGA) of acne
- Novel Anti-Biofilm AQUACEL™ Ag+ Dressing Demonstrates Positive Results in Hard-to-Heal Woundshttps://practicaldermatology.com/news/novel-anti-biofilm-aquacel-ag-dressing-demonstrates-positive-results-in-hard-to-heal-wounds/2458998/A new, multi-country, clinical evaluation study showed that AQUACEL™ Ag+ wound dressing demonstrated positive results in wounds, including those compromised by biofilm and/or infection. AQUACEL™ Ag+ dressings are designed to disrupt biofilm and kill infection-
- Cosmederm Bioscience Introduces Steve Massah as New Chief Operating Officerhttps://practicaldermatology.com/news/cosmederm-bioscience-introduces-steve-massah-as-new-chief-operating-officer/2459004/Cosmederm Bioscience has hired Steve Massah as its new Chief Operating Officer. As COO, Massah will provide strategic and tactical leadership, and management of manufacturing, product development, quality and product shipment and logistics. His work will ensure compliance with all government regu
- Investigational Atopic Dermatitis Cream Disappoints in Phase II Trialhttps://practicaldermatology.com/news/investigational-atopic-dermatitis-cream-disappoints-in-phase-ii-trial/2459003/Results from a phase II trial do not bode well for the future of the investigational atopic dermatitis cream MRX-6. The double-blind, parallel-group, vehicle-controlled study evaluated the safety and efficacy of MRX-6 cream 2% among 73 children suffering from mild-to-moderate atopic dermatitis. P
- Can-Fite Receives Notice of Allowance in US for Psoriasis Patenthttps://practicaldermatology.com/news/can-fite-receives-notice-of-allowance-in-us-for-psoriasis-patent/2459005/Can-Fite BioPharma Ltd. received a Notice of Allowance from the US Patent and Trademark Office for CF101 in the treatment of psoriasis. The patent, which is expected to be issued in the next few weeks, is titled, "Pharmaceutical Composition Comprising A3 Adenosine Receptor Agonist (IB-M
- Syneron Medical Appoints William Griffing to Newly Created Position of CEO of Syneron Candela North Americahttps://practicaldermatology.com/news/syneron-medical-appoints-william-griffing-to-newly-created-position-of-ceo-of-syneron-candela-north-america/2459009/Syneron Medical Ltd. appointed William Griffing to the newly created position of Chief Executive Officer of Syneron Candela North America, effective immediately. In this position, Mr. Griffing will be responsible for aligning and managing the Company's growth strategies for its North American
- Halozyme Appoints Jean-Pierre Bizzari, MD to Board Of Directorshttps://practicaldermatology.com/news/halozyme-appoints-jean-pierre-bizzari-md-to-board-of-directors/2459021/Halozyme Therapeutics, Inc. appointed of Jean-Pierre Bizzari, MD to its Board of Directors. Dr. Bizzari brings extensive experience in oncology drug development. "I am delighted to welcome Jean-Pierre to our Board of Directors," said Dr. Helen Torley, President and Chief Executi
- Cipher Pharmaceuticals appoints Lynne Bulger as Vice President, Medical Affairshttps://practicaldermatology.com/news/cipher-pharmaceuticals-appoints-lynne-bulger-as-vice-president-medical-affairs/2459022/Cipher Pharmaceuticals Inc. appointed Lynne Bulger as Vice President, Medical and Clinical Affairs to lead the Company's clinical development and medical affairs efforts for current and new pipeline products. Ms. Bulger has 27 years of experience in drug development in the pharmaceuti
- Dr. Zein Obagi's New Book Presents the Art and Science of Skin Healthhttps://practicaldermatology.com/news/dr-zein-obagis-new-book-present-the-art-and-science-of-skin-health/2459023/Zein Obagi, MD, founder of ZO Skin Health, Inc., has published a new book, The Art of Skin Health Restoration and Rejuvenation: The Science of Clinical Practice, Second Edition (CRC Press, Dec 2014). In it, he reveals the Zein Ob